Tuesday, 27 January 2015

Johnson and Johnson makes available Ebola Vaccine for Africa

Clinical trials for the Ebola vaccine have now begun and volunteers in Africa have now been administered the vaccine under the trials. Phase I of the clinical trials will end in April this year and is set to reach about 400,000 individuals.

The vaccine is intended to prevent people from catching the virus. The company has set a target to make available 2 million regimens by the end of 2015.

As the Ebola virus was speedily spreading in Liberia, Sierra Leone and the Guinea, Johnson and Johnson declared a vaccine expected at eradicating the deadly virus. They committed an amount of $200 million to boost the development of the vaccine.

“As a leader in the field of global health, we have a responsibility to act swiftly as Ebola continues to cause suffering among patients, families and health care workers in West Africa,” said Alex Gorsky, the chairman and CEO of Johnson & Johnson. Read More...


Post a Comment